Lipase
EstablishedLipase is the current preferred first-line marker for diagnosing acute pancreatitis, replacing amylase.
Lipase is the current go-to blood test for diagnosing pancreatitis, having replaced the older amylase test in most guidelines because it's more accurate and stays elevated longer, giving doctors a better window to catch the diagnosis.
Lipase is a pancreatic digestive enzyme that breaks down dietary fats; it is now the preferred first-line biomarker for diagnosing acute pancreatitis, having superseded amylase in current guidelines.
Elevated serum lipase (typically defined as 3x or more above the upper limit of normal) supports acute pancreatitis diagnosis when combined with characteristic abdominal pain and/or imaging findings, as part of the standard two-of-three diagnostic criteria.
Current guidelines (ACG, Japanese pancreatitis guidelines) explicitly recommend lipase over amylase, since lipase is more specific, rises faster, and stays elevated longer, giving a wider diagnostic window; serial monitoring of lipase levels is not recommended once the diagnosis is established, since levels don't correlate well with disease severity.
Diagnosis of acute pancreatitis requires meeting 2 of 3 criteria: characteristic abdominal pain, lipase (or amylase) at least 3x the upper limit of normal, and/or characteristic imaging findings — lipase alone above this threshold doesn't automatically confirm the diagnosis without the clinical picture.
Should not be repeated serially to monitor disease severity once the diagnosis is established.
- PMC. (2025). Diagnosis and Management of Acute Pancreatitis.
- CAP. Lipase in the Diagnosis of Acute Pancreatitis — For Clinicians.